FITC-Compatible Human CD19 Protein





Description	
Source	FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Pro20-Lys291.
Accession	P15391-1
Molecular Weight	The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
Wavelength	Excitation Wavelength: 490 nm
	Emission Wavelength: 520 nm
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC
Formulation and	Storage

Formulation and Storage

Formulation Supplied as 0.22 µm filtered solution in PBS (pH 7.4).

Storage Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller


quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.

Assay Data

Tris-Bis PAGE




FITC-Compatible Human CD19 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC




Assay Data



The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC.

FACS Data



Use 100 μ I FITC-Compatible Human CD19 (10 μ g/ml) to detect the positive rate of 1×10⁶ anti-CD19 CAR cells and FITC-labeled irrelevant protein (100 μ I, 10 μ g/ml) was served as a negative control.